Separation and identification of differentially expressed nuclear matrix proteins in breast carcinoma forming

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, . Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Pederson T. Thinking about a nuclear matrix. J Mol Biol 1998;277:147–59.
   PubMedGoogle Scholar
• Oge O, Atsü N, Kendi S, Ozen H. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 2001;32:367–70.
   PubMedGoogle Scholar
• Yoon GS, Lee H, Jung Y, Yu E, Moon HB, Song K, . Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res 2000;60:1117–20.
   PubMedGoogle Scholar
• Brünagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 2002;62:2437–42.
   PubMed Web of Science ®Google Scholar
• Lakshmanan Y, Subong EN, Partin AW. Differential nuclear matrix protein expression in prostate cancers: Correlation with pathologic stage. J Urol 1998;159:1354–8.
   PubMedGoogle Scholar
• Spencer VA, Samuel SK, Davie JR. Nuclear matrix proteins associated with DNA in situ in hormone-dependent and hormone-independent human breast cancer cell lines. Cancer Res 2000;60:288–92.
   PubMed Web of Science ®Google Scholar
• Spencer VA, Samuel SK, Davie JR. Altered profiles in nuclear matrix proteins associated with DNA in situ during progression of breast cancer cells. Cancer Res 2001;61:1362–6.
   PubMed Web of Science ®Google Scholar
• Michishita E, Kurahashi T, Suzuki T, Fukuda M, Fujii M, Hirano H, . Changes in nuclear matrix proteins during the senescence-like phenomenon induced by 5-chlorodeoxyuridine in HeLa cells. Exp Gerontol 2002;37:885–90.
   PubMed Web of Science ®Google Scholar
• Somasekhar MB, Gorski J. An estrogen-responsive element from the 5′-flanking region of the rat prolactin gene functions in MCF-7 but not in HeLa cells. Gene 1988;69:23–8.
   PubMedGoogle Scholar
• Fernandes DJ, Qiu J, Catapano CV. DNA topoisomerase II isozymes involved in anticancer drug action and resistance. Adv Enzyme Regul 1995;35:265–81.
   PubMedGoogle Scholar
• Balajee AS, May A, Bohr VA. Fine structural analysis of DNA repair in mammalian cells. Mutat Res 1998;404:3–11.
   PubMedGoogle Scholar
• Xiong XD, Li EM, Xu LY, Chen HB, Chen L, Cai WJ, . Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines. World J Gastroenterol 2003;9:2143–8.
   PubMedGoogle Scholar
• van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, . Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671–9.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.
   PubMed Web of Science ®Google Scholar
• Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, . Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 1993;53:3394–8.
   PubMed Web of Science ®Google Scholar
• Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994;69:743–8.
   PubMedGoogle Scholar
• Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, . Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis. Int J Cancer 1999;84:234–8.
   PubMedGoogle Scholar
• O’Callaghan-Sunol C, Gabai VL, Sherman MY. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 2007;67:11779–88.
   PubMed Web of Science ®Google Scholar
• Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468–75.
   PubMed Web of Science ®Google Scholar
• Dixit VD, Sridaran R, Edmonsond MA, Taub D, Thompson WE. Gonadotropin-releasing hormone attenuates pregnancy-associated thymic involution and modulates the expression of antiproliferative gene product prohibitin. Endocrinology 2003;144:1496–505.
   PubMedGoogle Scholar
• Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reprod Biol Endocrinol 2003;1:66.
   PubMedGoogle Scholar
• Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, . Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 2001;265:262–73.
   PubMed Web of Science ®Google Scholar
• Fusaro G, Wang S, Chellappan S. Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene 2002;21:4539–48.
   PubMedGoogle Scholar
• Chowdhury I, Xu W, Stiles JK, Zeleznik A, Yao X, Matthews R, . Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology 2007;148:206–17.
   PubMed Web of Science ®Google Scholar
• Kurzeder C, Sauer G, Deissler H. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Curr Cancer Drug Targets 2006;6:207–27.
   PubMedGoogle Scholar
• Wydner KL, McNeil JA, Lin F, Worman HJ, Lawrence JB. Chromosomal assignment of human nuclear envelope protein genes LMNA, LMNB1, and LBR by fluorescence in situ hybridization. Genomics 1996;32:474–8.
   PubMedGoogle Scholar
• Moss SF, Krivosheyev V, de Souza A, Chin K, Gaetz HP, Chaudhary N, . Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 1999;45:723–9.
   PubMed Web of Science ®Google Scholar